gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AMPHHealthcarePharmaceuticals

Amphastar Pharmaceuticals, Inc. (AMPH)

$28.02+3.32%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$28.02▲ 10.93% in range
Nov 4, 2025Low $16.87 · High $29.40Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Amphastar Pharmaceuticals closed at $28.02 on Nov 4, up 3.32%, 4.7% below its 52-week closing high. Volume of 644.9K shares was 1.56× its 20-day average (above normal).

Split-adjusted performance: +8.1% over one month, +17.2% over six months, +10.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $183.90M, up 5.4% from a year earlier, with a net margin of 16.5%.

Short interest was 4.3M shares at the Oct 15 settlement, down 1.6% from the prior report (14.9% of float, 9.8 days to cover).

Market cap$1.19B42.5M shares
Revenue · quarter$183.9M+5.4% YoY
Diluted EPS$0.67+4.7% YoY
P/E · TTM15.2×P/S 1.6×
Net margin16.5%Gross 50.8%
Dividend yieldNone
52-week range16.87 – 29.40−4.7% from high
Volume644.9K1.56× 20-day avg
Volatility · 60d31.3%Annualised
Short % of float14.9%9.9 days to cover
Net cash-$321.9MCash $290.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +6.4%1M +8.1%3M +41.4%6M +17.2%YTD +4.6%1Y +10.8%3Y −38.0%5Y +52.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum81
Revenue growth48
Net margin83
Value (low P/E)53
Size72

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.3M−1.6% vs prior
Days to cover9.9Settled Oct 15
% of float14.9%
Short vol. 10d62.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AMPHAmphastar Pharmaceuticals$28.02+3.32%+17.2%+5.4%16.5%15.2$1.19B
VSTMVerastem$9.85+0.82%+63.9%+1775.4%−86.5%—$1.20BCompare
AVLNAvalyn Pharma$27.47+2.46%————$1.22BCompare
MRVIMaravai LifeSciences Holdings$7.72+3.62%+95.9%+8.5%−24.1%—$1.15BCompare
MNKDMannkind$3.93+5.36%+10.4%+42.9%−17.4%—$1.26BCompare
SPTXSeaport Therapeutics$20.96+3.76%————$1.12BCompare
JANXJanux Therapeutics$18.18+2.02%+24.4%—−214.0%—$1.11BCompare
CRONCronos Group Inc. Common Share$3.51+3.85%+34.0%+59.5%45.4%18.5$1.29BCompare
NKTRNektar Therapeutics$38.48+1.91%−54.8%−9.3%−401.0%—$1.31BCompare

News about Amphastar Pharmaceuticals

All news →
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?Zacks Investment Research · Oct 6, 2026▲ PositiveZacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisZacks Investment Research · Aug 31, 2026Neutral

Quick answers

What does Amphastar Pharmaceuticals do?
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers.
What is AMPH's market cap?
$1.19B, based on the Nov 4 close of $28.02.
What is AMPH's P/E ratio?
15.2× trailing-twelve-month earnings of $78.55M.
Does Amphastar Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AMPH is sold short?
4.3M shares, 14.9% of float, as of Oct 15, 2026.
What sector is AMPH in?
Healthcare, in the Pharmaceuticals industry.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

HQ: Rancho Cucamonga, CA1,976 employeesListed Jun 25, 2014amphastar.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology